New approaches to combat antibiotic-resistant bacteria
NCCR AntiResist: Mono-center Study to Identify New Approaches to Combat Antibiotic-resistant Bacteria.
This study is trying to find new ways to fight tough bacteria that cause infections like urinary tract infections and pneumonia by looking at patient samples to understand how these germs work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Trial ID | NCT05017766 on ClinicalTrials.gov |
What this trial studies
This observational study investigates antimicrobial resistance (AMR) by analyzing patient samples from the University Hospital of Basel. It focuses on three clinical manifestations of infectious diseases: urinary tract infections, pneumonia, and deep-seated infections caused by high-priority bacteria such as E. coli and Klebsiella species. The study employs various advanced analytical techniques, including proteomic, metabolomic, and transcriptomic analyses, to understand the physiological properties of these pathogens in infected patients. The ultimate goal is to develop new strategies and compounds to combat superbugs effectively.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed urinary tract infections, pneumonia, or deep-seated infections caused by specific focus pathogens.
Not a fit: Patients under 18 years old or those who have refused consent for research and reuse of their data/samples may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to innovative treatments and strategies to combat antibiotic-resistant infections.
How similar studies have performed: Other studies have shown promise in similar approaches to understanding and combating antimicrobial resistance, making this a potentially impactful area of research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen: * E. coli * Klebsiella species * S. aureus * P. aeruginosa * Controls: no detectable bacteria in routine microbiology lab and no other infection site at inclusion of the sample and follow up for 10 days, signed general consent * Clinical controls without obtained samples, but with confirmed (i) urinary tract infection, (ii) pneumonia (including patients after lung transplantation, cystic fibrosis) or (iii) deep-seated infection with focus pathogen: * E. coli * Klebsiella species * S. aureus * P. aeruginosa Exclusion Criteria: * Patients who have refused research and reuse of their data/samples (e.g. general consent) or any other decline (e.g. Patientenverfügung). * other than one of the focus bacteria in routine microbiology lab * Age: \<18 years * Controls without signed general consent
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Nina Khanna, Prof. — University Hospital Basel, Division of Infectiology
- Study coordinator: Nina Khanna, Prof.
- Email: nina.khanna@usb.ch
- Phone: +41 61 328 73 25
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.